Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

M. Rovaris, M. Codella, L. Moiola, A. Ghezzi, M. Zaffaroni, G. Mancardi, E. Capello, F. Sardanelli, G. Comi, M. Filippi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.

Original languageEnglish
Pages (from-to)1429-1432
Number of pages4
JournalNeurology
Volume59
Issue number9
Publication statusPublished - Nov 12 2002

Fingerprint

Gadolinium
Glatiramer Acetate
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. / Rovaris, M.; Codella, M.; Moiola, L.; Ghezzi, A.; Zaffaroni, M.; Mancardi, G.; Capello, E.; Sardanelli, F.; Comi, G.; Filippi, M.

In: Neurology, Vol. 59, No. 9, 12.11.2002, p. 1429-1432.

Research output: Contribution to journalArticle

Rovaris, M, Codella, M, Moiola, L, Ghezzi, A, Zaffaroni, M, Mancardi, G, Capello, E, Sardanelli, F, Comi, G & Filippi, M 2002, 'Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses', Neurology, vol. 59, no. 9, pp. 1429-1432.
Rovaris M, Codella M, Moiola L, Ghezzi A, Zaffaroni M, Mancardi G et al. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology. 2002 Nov 12;59(9):1429-1432.
Rovaris, M. ; Codella, M. ; Moiola, L. ; Ghezzi, A. ; Zaffaroni, M. ; Mancardi, G. ; Capello, E. ; Sardanelli, F. ; Comi, G. ; Filippi, M. / Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. In: Neurology. 2002 ; Vol. 59, No. 9. pp. 1429-1432.
@article{dc9d58dd33c84b1f818b655ed354f538,
title = "Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses",
abstract = "This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.",
author = "M. Rovaris and M. Codella and L. Moiola and A. Ghezzi and M. Zaffaroni and G. Mancardi and E. Capello and F. Sardanelli and G. Comi and M. Filippi",
year = "2002",
month = "11",
day = "12",
language = "English",
volume = "59",
pages = "1429--1432",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

AU - Rovaris, M.

AU - Codella, M.

AU - Moiola, L.

AU - Ghezzi, A.

AU - Zaffaroni, M.

AU - Mancardi, G.

AU - Capello, E.

AU - Sardanelli, F.

AU - Comi, G.

AU - Filippi, M.

PY - 2002/11/12

Y1 - 2002/11/12

N2 - This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.

AB - This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.

UR - http://www.scopus.com/inward/record.url?scp=0037069306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037069306&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 1429

EP - 1432

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -